Clinical trials: Mild to Moderate Hypertension, open to volunteers
- Condition Mild to Moderate Hypertension
- Status Open to volunteers
- Funder type Industry (pharma, biotech, devices)
Primary Open Angle Glaucoma
Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma
A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to…
- Trial name
- CATALYST (NCT05564091)
- Testing
- Cataract surgery combined with ab-interno canaloplasty utililzing the iTrack Advance canaloplasty device, Cataract surgery
- Where
- 4 sites in United States, Germany
- Volunteers
- 78 people
- Sponsor
- Nova Eye, Inc.
Glaucoma, Ocular Hypertension
Evaluation of the Safety, Efficacy, Dose Response of the Bimatoprost Drug Ring System (BIM-DRS) in Pseudophakic Patients Diagnosed With Open Angle Glaucoma or Ocular Hypertension
The goal of this clinical trial is to learn if two different doses of the SpyGlass Bimatoprost-Drug Ring System (BIM-DRS) work to treat adult pseudophakic patients with either glaucoma or ocular hypertension.
- Trial name
- NCT07641296
- Testing
- BIM-DRS Low Dose, BIM-DRS High Dose, SpyGlass IOL with silicone pads (no drug)
- Volunteers
- 24 people
- Sponsor
- SpyGlass Pharma, Inc.
Mild-to-moderate Essential Hypertension
A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients
SYH9056 tablets are a combination of valsartan and levamlodipine maleate. This is a multicenter, randomized, double-blind, parallel-controlled phase III study, designed to validate the efficacy and safety of SYH9056 tablets in…
- Trial name
- NCT06771245
- Testing
- SYH9056, Levamlodipine, Valsartan
- Volunteers
- 606 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Overweight, Obesity
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received…
- Conditions
- Overweight, Obesity, Hypertensive
- Trial name
- NCT07469800
- Testing
- IBI362
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Hypertension
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
- Trial name
- NCT07553442
- Testing
- ALN-AGT01 RVR, Zilebesiran
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
A Study of IBI3016 in Japanese Participants
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
- Trial name
- NCT07838220
- Testing
- IBI3016 Dose 4, IBI3016 Dose 3, IBI3016 Dose 2
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol
A Study of BEBT-701 in Patients With Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol（LDL-C）
This Phase I/II clinical trial is designed to evaluate, through a single-dose Phase I segment and a multiple-dose Phase II segment, the safety/tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) characteristics…
- Trial name
- NCT07368608
- Testing
- BEBT-701 Injection
- Where
- China
- Volunteers
- 340 people
- Sponsor
- BeBetter Med Inc
Glaucoma
Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
- Trial name
- NCT06057051
- Testing
- iStent Infinite
- Where
- United States
- Volunteers
- 245 people
- Sponsor
- Glaukos Corporation